ZA200504408B - Continuous process for the preparation of fructopyranose sulfamate derivatives - Google Patents
Continuous process for the preparation of fructopyranose sulfamate derivatives Download PDFInfo
- Publication number
- ZA200504408B ZA200504408B ZA200504408A ZA200504408A ZA200504408B ZA 200504408 B ZA200504408 B ZA 200504408B ZA 200504408 A ZA200504408 A ZA 200504408A ZA 200504408 A ZA200504408 A ZA 200504408A ZA 200504408 B ZA200504408 B ZA 200504408B
- Authority
- ZA
- South Africa
- Prior art keywords
- compound
- formula
- organic solvent
- solvent
- straight
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims description 24
- 238000010924 continuous production Methods 0.000 title claims description 15
- -1 fructopyranose sulfamate derivatives Chemical class 0.000 title claims description 9
- 150000001875 compounds Chemical class 0.000 claims description 175
- 239000003960 organic solvent Substances 0.000 claims description 89
- 239000002904 solvent Substances 0.000 claims description 83
- 238000000034 method Methods 0.000 claims description 76
- 230000008569 process Effects 0.000 claims description 70
- YBBRCQOCSYXUOC-UHFFFAOYSA-N sulfuryl dichloride Chemical compound ClS(Cl)(=O)=O YBBRCQOCSYXUOC-UHFFFAOYSA-N 0.000 claims description 46
- XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical group COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 claims description 44
- 150000001983 dialkylethers Chemical class 0.000 claims description 44
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 claims description 42
- 150000004945 aromatic hydrocarbons Chemical class 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 30
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 125000004122 cyclic group Chemical group 0.000 claims description 24
- 150000004292 cyclic ethers Chemical class 0.000 claims description 22
- 229910021529 ammonia Inorganic materials 0.000 claims description 18
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical group C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 16
- 125000000217 alkyl group Chemical group 0.000 claims description 13
- 150000007530 organic bases Chemical class 0.000 claims description 12
- 239000001257 hydrogen Substances 0.000 claims description 11
- 229910052739 hydrogen Inorganic materials 0.000 claims description 11
- 239000003937 drug carrier Substances 0.000 claims description 9
- 150000007529 inorganic bases Chemical class 0.000 claims description 8
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 6
- 150000002431 hydrogen Chemical class 0.000 claims description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 4
- 239000003039 volatile agent Substances 0.000 claims description 4
- 125000002009 alkene group Chemical group 0.000 claims description 3
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 3
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims 1
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 54
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 36
- 239000000243 solution Substances 0.000 description 35
- 239000002585 base Substances 0.000 description 31
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 30
- 239000000047 product Substances 0.000 description 24
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 22
- PSSHGMIAIUYOJF-XBWDGYHZSA-N [(3as,5ar,8ar,8bs)-2,2,7,7-tetramethyl-5,5a,8a,8b-tetrahydrodi[1,3]dioxolo[4,5-a:5',3'-d]pyran-3a-yl]methanol Chemical compound C1O[C@@]2(CO)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 PSSHGMIAIUYOJF-XBWDGYHZSA-N 0.000 description 19
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 18
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 18
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 12
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 12
- 239000002244 precipitate Substances 0.000 description 12
- KJADKKWYZYXHBB-XBWDGYHZSA-N Topiramic acid Chemical compound C1O[C@@]2(COS(N)(=O)=O)OC(C)(C)O[C@H]2[C@@H]2OC(C)(C)O[C@@H]21 KJADKKWYZYXHBB-XBWDGYHZSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 10
- 239000008096 xylene Substances 0.000 description 10
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 9
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 9
- XTHPWXDJESJLNJ-UHFFFAOYSA-M chlorosulfate Chemical compound [O-]S(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-M 0.000 description 9
- 239000011550 stock solution Substances 0.000 description 9
- 229960004394 topiramate Drugs 0.000 description 9
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 8
- 239000012141 concentrate Substances 0.000 description 8
- 125000001424 substituent group Chemical group 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000011437 continuous method Methods 0.000 description 6
- 239000012527 feed solution Substances 0.000 description 6
- 238000011068 loading method Methods 0.000 description 6
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical group [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 5
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- QCQCHGYLTSGIGX-GHXANHINSA-N 4-[[(3ar,5ar,5br,7ar,9s,11ar,11br,13as)-5a,5b,8,8,11a-pentamethyl-3a-[(5-methylpyridine-3-carbonyl)amino]-2-oxo-1-propan-2-yl-4,5,6,7,7a,9,10,11,11b,12,13,13a-dodecahydro-3h-cyclopenta[a]chrysen-9-yl]oxy]-2,2-dimethyl-4-oxobutanoic acid Chemical compound N([C@@]12CC[C@@]3(C)[C@]4(C)CC[C@H]5C(C)(C)[C@@H](OC(=O)CC(C)(C)C(O)=O)CC[C@]5(C)[C@H]4CC[C@@H]3C1=C(C(C2)=O)C(C)C)C(=O)C1=CN=CC(C)=C1 QCQCHGYLTSGIGX-GHXANHINSA-N 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 238000001816 cooling Methods 0.000 description 4
- 238000001704 evaporation Methods 0.000 description 4
- 230000008020 evaporation Effects 0.000 description 4
- 238000004817 gas chromatography Methods 0.000 description 4
- 239000011521 glass Substances 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 229910001220 stainless steel Inorganic materials 0.000 description 4
- 239000010935 stainless steel Substances 0.000 description 4
- 150000003512 tertiary amines Chemical class 0.000 description 4
- 238000011282 treatment Methods 0.000 description 4
- 238000005292 vacuum distillation Methods 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 239000005715 Fructose Substances 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- PXIPVTKHYLBLMZ-UHFFFAOYSA-N Sodium azide Chemical compound [Na+].[N-]=[N+]=[N-] PXIPVTKHYLBLMZ-UHFFFAOYSA-N 0.000 description 2
- 239000002250 absorbent Substances 0.000 description 2
- 230000002745 absorbent Effects 0.000 description 2
- 150000001412 amines Chemical class 0.000 description 2
- 150000001540 azides Chemical class 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- WRJWRGBVPUUDLA-UHFFFAOYSA-N chlorosulfonyl isocyanate Chemical compound ClS(=O)(=O)N=C=O WRJWRGBVPUUDLA-UHFFFAOYSA-N 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 206010015037 epilepsy Diseases 0.000 description 2
- 239000011552 falling film Substances 0.000 description 2
- 239000010408 film Substances 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 125000006239 protecting group Chemical group 0.000 description 2
- 150000003222 pyridines Chemical class 0.000 description 2
- 239000000376 reactant Substances 0.000 description 2
- 230000035484 reaction time Effects 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910000104 sodium hydride Inorganic materials 0.000 description 2
- 239000012453 solvate Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- WJXREUZUPGMAII-UHFFFAOYSA-N sulfurazidic acid Chemical compound OS(=O)(=O)N=[N+]=[N-] WJXREUZUPGMAII-UHFFFAOYSA-N 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- LKDRXBCSQODPBY-VRPWFDPXSA-N D-fructopyranose Chemical compound OCC1(O)OC[C@@H](O)[C@@H](O)[C@@H]1O LKDRXBCSQODPBY-VRPWFDPXSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 229920003266 Leaf® Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000013019 agitation Methods 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 230000001773 anti-convulsant effect Effects 0.000 description 1
- 239000001961 anticonvulsive agent Substances 0.000 description 1
- 229960003965 antiepileptics Drugs 0.000 description 1
- 125000003710 aryl alkyl group Chemical group 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 238000010923 batch production Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 238000009903 catalytic hydrogenation reaction Methods 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000004296 chiral HPLC Methods 0.000 description 1
- YUMNNMSNSLHINV-UHFFFAOYSA-N chloro sulfamate Chemical compound NS(=O)(=O)OCl YUMNNMSNSLHINV-UHFFFAOYSA-N 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 229960001270 d- tartaric acid Drugs 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000004880 explosion Methods 0.000 description 1
- 239000002360 explosive Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 238000001640 fractional crystallisation Methods 0.000 description 1
- 239000012458 free base Substances 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000003365 glass fiber Substances 0.000 description 1
- 125000001072 heteroaryl group Chemical group 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 125000001147 pentyl group Chemical group C(CCCC)* 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- LPNYRYFBWFDTMA-UHFFFAOYSA-N potassium tert-butoxide Chemical compound [K+].CC(C)(C)[O-] LPNYRYFBWFDTMA-UHFFFAOYSA-N 0.000 description 1
- 238000004237 preparative chromatography Methods 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000012312 sodium hydride Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-M sulfamate Chemical class NS([O-])(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-M 0.000 description 1
- IIACRCGMVDHOTQ-UHFFFAOYSA-N sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 description 1
- JRIOFYJRUMRUOC-UHFFFAOYSA-N sulfurochloridic acid Chemical compound OS(Cl)(=O)=O.OS(Cl)(=O)=O JRIOFYJRUMRUOC-UHFFFAOYSA-N 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
Landscapes
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Description
CONTINUOUS PROCESS FOR THE PREPARATION OF FRUCTOPYRANOSE
SULFAMATE DERIVATIVES
This application claims the benefit of U. 8S. . Provisional Application 60/422,558, filed on October 31, 2002, which is incorporated by reference herein in its entirety.
The present invention relates to a continuous process for the preparation of fructopyranose sulfamate derivatives of the general formula (I) 0) H 1
X s( NR ial
R3
R® R* Q) wherein R', R3®, R%*, R%, R® and X are as hereinafter defined.
Sulfamates of the formula (I) 0 N rR
X 4 real
R3
R® rR? 0] wherein X is O or CH, and RY, R?}, R*, R® and R® are as hereinafter defined, are known compounds that have } been found to exhibit anticonvulsant activity and are therefore useful in the treatment of conditions such as epilepsy. These compounds are disclosed in U.S. Pat.
No. 4,582,916 and U.S. Pat. No. 4,513,006, which also disclose processes for the preparation of said compounds; and which are hereby incorporated by ] reference. . One process disclosed in the above referenced patents is a process for the preparation of the compounds of formula (I) comprising reacting an alcohol of the formula RCH,OH with a chlorosulfamate of the formula C1SO,NH, or CLlSO,NHR' in the presence of a base such as potassium t-butoxide or sodium hydride at a temperature of about -20°C to 25°C and in a solvent such as toluene, tetrahydrofuran or dimethylformamide, where
R is a moiety of the formula (II)
X
RS
~<a (In
RS R*
This process has two major disadvantages, particularly for large scale synthesis. One disadvantage is that the process calls for a combination of NaH and DMF which has an uncontrollable exotherm and is therefore potentially explosive. See J. Buckley et al., Chemical & Engineering News, July 12, 1982, page 5; and G. DeWail, Chemical & Engineering News, Sept. 13, : 1982. Another disadvantage is that the process also uses highly toxic and corrosive chlorosulfonyl isocyanate (CSI) to prepare the commercially unavailable - sulfamyl chloride (ClSO,NH,).
Another process for the preparation of compounds of formula (I) disclosed in the above mentioned U.S. Pat.
No. 4,513,006 comprises reacting an alcohol of the formula RCH;0H with sulfuryl chloride of the formula
S0,Cl, in the presence of a base such as triethylamine or . pyridine at a temperature of about -40°C to 25°C in a diethyl ether or methylene chloride solvent to produce a * chlorosulfate of the formula RCH,0S0,Cl. The chlorosulfate of the formula RCH,0SO0.Cl may then be reacted with an amine of the formula R!NH, at a temperature of about -40°C to 25°C in a methylene chloride or acetonitrile solvent to produce the compound of formula (I). This process utilizing diethyl ether, methylene chloride and acetonitrile solvents produces relatively low yields of the desired end product of formula (I).
A third process disclosed in the two patents mentioned above comprises reacting the chlorosulfate of formula RCH,080,Cl (formed as previously described) with a metal azide such as sodium azide in a solvent such as methylene chloride or acetonitrile to yield an azidosulfate of the formula RCH,0S80,N;. The azidosulfate is then reduced to the compound of formula (I) wherein R! is hydrogen, by catalytic hydrogenation.
A disadvantage with this process is that explosions may occur when handling the azide compounds. Also, the process contains an additional chemical transformation involving the reduction of the azide to the NH; moiety. ] 30 Maryanoff et al. in US 5,387,700 disclose a process } for the preparation of compounds of formula (I) which comprises reacting an alcohol of the formula RCH;OH with sulfuryl chloride in the presence of a base, in a solvent selected from the group consisting of toluene, t-butyl methyl ether and tetrahydrofuran, to form a chlorosulfate intermediate of the formula RCH,0S0,Cl. In . a second step, the chlorosulfate of formula RCH;0S0:Cl is reacted with an amine of the formula RWNH,, in a solvent . selected from the group consisting of tetrahydrofuran, t-butyl methyl ether and lower alkanol (e.g. methanol or ethanol) to form the compound of formula (I). io One disadvantage of this process is that the compound of formula (I) is prepared in a batch process wherein the first reaction is carried out, the solvent is removed, the product is isolated, the isolated solid is re-dissolved in a second solvent and then reacted to the final product. This results in a process which requires isolation of a semi-stable, thermally labile
ROS0,Cl1 intermediate.
It is an object of the present invention to provide a continuous process for the preparation of the compounds of formula (I), which does not require changes in solvent systems, which uses readily available materials, which can be carried out under safe conditions, which will produce relatively high yields and /or which will allow for the production of a greater amount of material per unit time per reactor space (i.e which will allow for production of a greater amount of material in smaller equipment).
The present invention is directed to a continuous process for the preparation of compounds of formula (I)
0 N—R!
X ho {5
RS
R® R (1) ’ wherein
X is selected from CH, or O;
R! is selected from the group consisting of hydrogen and C-zalkyl;
R®, R*, R® and R® are each independently selected from hydrogen or lower alkyl and, when X is CH, R® and
R® may be alkene groups joined to form a benzene ring and, when X is O, R® and R* and/or R® and R® together may be a methylenedioxy group of the formula:
R’ 0-9
X
R® 0% wherein
R’ and R® are same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring; comprising
SOL!
X OH X oO oe
RS R4 R® R* (IV) (V) (A) reacting a suitably substituted compound of : formula (IV) with sulfuryl chloride; in the presence of an organic or inorganic base;
in a first organic solvent comprising at least one solvent selected from a cyclic ether, a straight or branched chain dialkyl ether, an aromatic hydrocarbon, . or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent; . to form the corresponding compound of formula (V); 80.Cl SO; ~NHR'
X 0 X 0 \
R® R? VD) RS R4 v) ()) (B) reacting the compound of formula (V)} with a suitably substituted compound of formula (VI); in a second organic solvent comprising at least the solvent used in step (A); to form the corresponding compound of formula (1).
The present invention is further directed to a continuous process for the preparation of the compound of formula (III)
NH,
Os¢
Vas
O &©O © on ) CE 3
S xX ~o . ” also known as topiramate, a compound of formula (I) : wherein X is O, R! is hydrogen, R?® and R! and R® and R° are each taken together to form
TNC
3 0) CHs . comprising
S0:Cl
O &—OH O&O ow ~O + SOC, — OW ~0
NI ; N ~o oN ro oA (IVa) (Va) (Aa) reacting a compound of formula (IVa) with sulfuryl chloride; in the presence of an organic or inorganic base; in a first organic solvent comprising at least one solvent selected from a cyclic ether, a straight or branched chain dialkyl ether, an aromatic hydrocarbon, or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent; to form the corresponding compound of formula (va) ; _ 1 ° S02Cl : SO: NHR
SO O&O ow - 0 + NH; —_— a (0s (va) (nn (Ba) reacting the compound of formula (Va) with ammonia; in a second organic solvent comprising at least the solvent used in step (A); } to form the corresponding compound of formula (III).
The present invention is further directed to a compound prepared according to any of the processes described herein.
Illustrative of the invention is a pharmaceutical : composition comprising a pharmaceutically acceptable carrier and a compound prepared according to any of the processes described above.
An illustration of the invention is a pharmaceutical composition made by mixing a pharmaceutically acceptable carrier and a compound prepared according to any of the processes described above.
Illustrating the invention is a process for making a pharmaceutical composition comprising mixing a pharmaceutically acceptable carrier and a compound prepared according to any of the processes described above.
Another example of the invention is the use of a compound prepared according to any of the processes described herein in the preparation of a medicament for treating epilepsy.
In an embodiment of the present invention, the second organic solvent (used in step (B)) is the same as © 30 the first organic solvent (used in step (A)). In another embodiment of the present invention, the first organic solvent (used in step (A)) and the second organic solvent (used in step (B)) are both glyme.
As used herein, the term "reactor" shall mean a continuous reactor, for example a continuous stirred tank reactor (CSTR), a plug flow reactor, a tower reactor, and the like. Preferably, the continuous reactor is a , continuous stirred tank reactor.
As used herein, the term "residence time" shall mean the average amount of time a particle of reactant or reactants spends within the reactor.
As used herein, the term “alkyl” whether used alone or as part of a substituent group, include straight and branched alkyl chains. For example, alkyl radicals include methyl, ethyl, propyl, isopropyl, butyl, isobutyl, sec-butyl, t-butyl, pentyl and the like.
Unless otherwise noted, the term “lower” when used with alkyl shall mean a carbon chain composition of 1-4 carbon atoms.
With reference to substituents, the term “independently” means that when more than one of such substituents is possible, such substituents may be the same or different from each other.
When a particular group is "substituted" (e.g., alkyl, phenyl, aryl, aralkyl, heteroaryl), that group may have one or more substituents, preferably from one to three substituents, more preferably from one to two ) 30 substituents, independently selected from the list of substituents.
The term “subject” as used herein, refers to an animal, preferably a mammal, most preferably a human, who is or has been the object of treatment, observation or . experiment. - The term “therapeutically effective amount” as used herein, means that amount of active compound or pharmaceutical agent that elicits the biological or medicinal response in a tissue system, animal or human that is being sought by a researcher, veterinarian, medical doctor or other clinician, which includes alleviation of the symptoms of the disease or disorder being treated.
As used herein, the term “composition” is intended to encompass a product comprising the specified ingredients in the specified amounts, as well as any product which results, directly or indirectly, from combinations of the specified ingredients in the specified amounts.
Abbreviations used in the specification, particularly the Schemes and Examples, are as follows:
CS or = Diacetone-Bf-D-fructose chlorosulfate chlorosulfate
CSTR = Continuous stirred tank reactor
DAF = Diacetone-B-D-fructose
DIPEA = Diisopropylethylamine } DMF = N,N-Dimethylformamide
GC = Gas Chromatography . glyme = Ethylene glycol dimethyl ether
HPLC = High pressure liquid chromatography
MTBE = Methyl-t-butyl ether sc = Sulfuryl chloride
TEA = Triethylamine . THF = Tetrahydrofuran
TPM = Topiramate
The present invention is directed to a continuous process for the preparation of a compound of formula (I) 0 N—R'
X ( aol
RS
R® RR (1) wherein
X is selected from CH, or O; i R® is selected from the group consisting of hydrogen and C;_salkyl;
R3, R*, R® and R® are each independently selected from hydrogen or lower alkyl and, when X is CH,, R® and
R® may be alkene groups joined to form a benzene ring and, when X is 0, R?® and R* and/or R®'and R® together may be a methylenedioxy group of the formula:
R’ 0-3
X
R® 0-3 wherein
R? and R® are the same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring.
More particularly, the present invention is directed to a continuous process for the preparation of a compound of formula (I) as outlined in Scheme 1.
Step (A):
SOC
X OH x J (Jor + SO,Cly, —— aa
RP R* RS R¢
WV v)
Step (B):
SOC S0,~NHR'
X 0 X 0
Jor + R'—NH, — (Yo
RS _* (VI) RS =
Vv) 0)
Scheme 1
Accordingly, in step (A), a suitably substituted compound of formula (IV), a known compound or compound i0 prepared by known methods, and a base are dissolved in a first organic solvent, and reacted with sulfuryl chloride; wherein the base is an inorganic base such as
Na,COs3, K,CO,;, NaHCO;, and the like, or an organic base such as a tertiary amine base such as pyridine, a pyridine derivative, TEA, DIPEA, and the like; preferably an organic tertiary amine base, more preferably pyridine; wherein, preferably the base does not react with the compound of formula (IV) or the sulfuryl chloride; : wherein the first organic solvent comprises at least one solvent selected from a cyclic ether, such as pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme, MTBE, and the like; an aromatic hydrocarbon solvent such as toluene, benzene, xylene, and the like; or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent; preferably the first ] organic solvent comprises at least one solvent selected from a cyclic or straight or branched chain dialkyl : ether such as THF, pyran, glyme, MTBE, and the like; more preferably the first organic solvent comprises at least glyme; wherein the sulfuryl chloride is preferably present in an amount greater than about 0.9 moles per mole of the compound of formula (IV); more preferably, the molar ratio of the compound of formula (IV) to the sulfuryl chloride is in the range of from about 1:0.9 to about 1:1.5; more preferably still, the molar ratio of the compound of formula (IV) to the sulfuryl chloride is in the range of from about 1:1.0 to about 1:1.05; wherein the base is preferably present in an amount greater than about 1 molar equivalent of the compound of formula (IV); more preferably, the molar ratio of the compound of formula (IV) to the base is greater than or equal to about 1:1.05; more preferably still, the molar ratio of the compound of formula (IV) to the base is in the range of from about 1:1.05 to about 1:1.20; more preferably still, the molar ratio of the compound of formula (IV) to the base is about 1:1.05;
’ wherein the temperature of the reaction is preferably maintained at less than about 50°C, more preferably at about 0°C to about 20°C, most preferably at
) about 0°C; to form a solution containing the corresponding : compound of formula (V) and a precipitate of the base hydrochloride salt.
In an embodiment of the present invention, the first organic solvent (used in Step (A)) is selected from the group consisting of a cyclic ether, such as ] pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme, MIBE, and . the like; an aromatic hydrocarbon solvent such as toluene, benzene, Xylene, and the like; or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent. Preferably, the first organic solvent (used in step (A)) is selected from a cyclic or straight or branched dialkyl ether such as
THF, pyran, glyme, MTBE, and the like, more preferably the first organic solvent (used in step (A)) is glyme.
In an embodiment of the present invention, the i first organic solvent (used in Step (A)) is selected from the group consisting of a cyclic ether, a straight or branched chain dialkyl ether, and an aromatic hydrocarbon solvent; wherein the first organic solvent is other than tetrahydrofuran or t-butyl methyl ether.
In an embodiment of the present invention, step (A) _ of the reaction is run such that the compound of formula (IV) and the base, dissolved in the first organic solvent, are reacted with neat sulfuryl chloride, by continuously feeding one reaction stream containing the compound of formula (IV) and the base dissolved in the first organic solvent and a second reaction stream containing the sulfuryl chloride into a continuous reactor, preferably a CSTR. In another embodiment of the present invention, the sul furyl chloride is dissolved in the same organic solvent as that used to dissolve the compound of formula (IV) and the base (i.e. the first organic solvent). . preferably, the solution containing the compound of formula (V) and the precipitate of the base : hydrochloride salt is filtered, according to known methods, to remove the precipitate.
Preferably, the solution containing the compound of formula (V) is concentrated by known batch or continuous methods, for example by evaporation of the solvent (such as by falling film or wiped film evaporation), or by vacuum distillation, to yield a concentrate of the compound of formula (V). In an embodiment of the present invention, the solution containing the compound of formula (V) is concentrated to less than or equal to about half the original mass of the solution. In another embodiment of the present invention, the solution containing the compound of formula (V) is concentrated to an oil. . Wherein the compound of formula (IV) is reacted with greater than about 1 equivalent of sulfuryl chloride, the solution containing the compound of formula (V) is preferably concentrated, according to known batch or continuous method, to remove at least about 70% of solvent mass.
Wherein the compound of formula (IV) is reacted with about 1 equivalent of sulfuryl chloride, the solution containing the compound of formula (V) is preferably concentrated, according to known batch or continuous method, to remove at least about 20% of solvent mass. . In an embodiment of the present invention, the solution containing the compound of formula (V) is : treated to remove volatiles. Suitable treatments include, but are not limited to, vacuum distillation, concentration, stripping, passing through activated carbon or other absorbent, and the like.
The concentrate of the compound of formula (V) is dissolved in a second organic solvent comprising at least the solvent used in step (A) (i.e. the first organic solvent), preferably comprising at least one solvent selected from a cyclic ether, such as pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme, MTBE, and the like; an aromatic hydrocarbon solvent such as toluene, benzene, xylene, and the like; or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent. Preferably, the concentrate of the compound of formula (V) is dissolved in the same organic solvent used in step (A) above.
Preferably, the concentrate of the compound of formula (V) is dissolved to a final mass ratio of the solvent to the compound of formula (V) in the range of from about 2:1 to about 10:1, more preferably to a mass ratio of the solvent to the compound of formula (V) of about 6:1, to yield a reaction stream for use in step (B), hereinafter referred to as the third reaction stream, containing the compound of formula (V).
In step (B), the compound of formula (V) is reacted with a suitably substituted compound of formula (Vi), a known compound or compound prepared by known methods, . in a second organic solvent comprising at least the solvent used in step (A); : wherein the second organic solvent comprises at least one solvent selected from a cyclic ether, such as pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme, MTBE, and the like; an aromatic hydrocarbon solvent such as toluene, benzene, xylene, and the like; or a mixture of : a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent; preferably the second organic solvent comprises at least one solvent selected from a cyclic or straight or branched dialkyl ether such as THF, pyran, glyme, MIBE, and the like; more preferably the second organic solvent comprises at least glyme; more preferably still, the second organic solvent is the same as the first organic solvent; more preferably still, the second organic solvent is glyme; wherein the compound of formula (VI) is preferably present in an amount greater than about 1 molar equivalent of the compound of formula (V); more preferably, the molar ratio of the compound of formula (VI) to the compound of formula (V) is greater than or equal to about 2:1; more preferably still, the molar ratio of the compound of formula (VI) to the compound of formula (V) is about 5:1; wherein the temperature .of the reaction is preferably maintained in the range of about -30°C to about 50°C, more preferably in the range of about 0°C to about 30°C, more preferably still at about 20°C;
to form a solution of the compound of formula (I) and a precipitate. . When the compound of formula (VI) is ammonia gas, the ammonia gas is preferably fed into the reactor at a : controlled pressure or flow rate, more preferably, at a pressure in the range of less than or equal to about 30 psia, more preferably still, at a pressure in a range of about 15 psia to about 20 psia, more preferably still, at a pressure of about 19 psia.
In an embodiment of the present invention, the second organic solvent (used in step (B)) is selected from the group consisting of a cyclic ether, such as pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme, MTBE, and the like; an aromatic hydrocarbon solvent such as toluene, benzene, xylene, and the like; or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent. Preferably, the second organic solvent (used in step (B)) is selected from a cyclic or straight or branched chain dialkyl ether such as THF, pyran, glyme, MTBE, and the like, more preferably the second organic solvent (used in step (B)) is glyme.
In an embodiment of the present invention, the second organic solvent (used in Step (B)) is selected from the group consisting of a cyclic ether, a straight ) 30 or branched chain dialkyl ether and an aromatic hydrocarbon solvent; wherein the second organic solvent is other than tetrahydrofuran or t-butyl methyl ether.
In another embodiment of the present invention, the second organic solvent (used in step (B)) comprises the solvent used in step (A) (i.e. the first organic ) solvent) . . Preferably, the solution containing the compound of formula (I) and the precipitate is filtered by known methods, to remove the precipitate.
In an embodiment of the invention, the process for the preparation of a compound of formula (I) is run in two continuous stirred tank reactors (CSTRs).
Preferably, step (A) is run such that the residence time in the first CSTR is about 1 hour. Preferably, step (B) is run such that the residence time in the second CSTR is about 3 hours. Preferably, step (B) is run such that the third reaction stream and the compound of formula (VI) are introduced above surface into the CSTR. 20. The present invention is further directed to a continuous process for the preparation of a compound of formula (III), also known as Topiramate, as outlined in
Scheme 2.
Step (Aa):
SO,Cli 0) ——— 2
S OH 0) 0 we S ou Oo + SO,Cl, —_— ow . lo)
SI \
SY : (IVa) (Va)
Step (Ba):
SOC SO,—NH, 0] 0 0] «0 eo NAT ro Se (Va) (1)
Scheme 2
Accordingly, in step (Ra), a compound of formula (IVa), a compound also known as diacetone fructose (DAF), and a base are dissolved in a first organic solvent, and reacted with sulfuryl chloride; wherein the base is an inorganic base such as
Na,COs;, K;CO;, NaHCO;, and the like, or an organic base such as a tertiary amine base such as pyridine, a pyridine derivative, TEA, DIPEA, and the like; preferably an organic tertiary amine base, more preferably pyridine; wherein, preferably the base does not react with the compound of formula (IVa) or the sul furyl chloride; wherein the first organic solvent comprises at least one solvent selected from a cyclic ether, such as pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme, MTBE, and the like; an aromatic hydrocarbon solvent such as toluene, benzene, xylene, and the like; or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent; preferably the first organic solvent comprises at least one solvent selected from a cyclic or straight or branched chain dialkyl ) ether such as THF, pyran, glyme, MIBE, and the like; more preferably the first organic solvent comprises at least glyme; more preferably still, the first organic solvent is glyme;
wherein the sulfuryl chloride is preferably present in an amount greater than about 0.9 moles per mole of the compound of formula (IVa); more preferably, the } molar ratio of the compound of formula (IVa) to the sulfuryl chloride is in the range of from about 1:0.9 to . about 1:1.5; more preferably still, the molar ratio of the compound of formula (IVa) to the sulfuryl chloride is in the range of from about 1:1.0 to about 1:1.05; wherein the base is preferably present in an amount greater than about 1 molar equivalent relative to the compound of formula (IVa); more preferably, the molar ratio of the compound of formula (IVa) to the base is greater than or equal to about 1:1.05; more preferably, the molar ratio of the compound of formula (IVa) to the base is in the range of from about 1:1.05 to about 1:1.20; more preferably still, the molar ratio of the compound of formula (IVa) to the base is about 1:11.05; wherein the temperature of the reaction is preferably maintained at less than about 50°C, more preferably at about 0°C to about 20°C, most preferably at about 0°C; to form a solution containing the corresponding compound of formula (Va) and a precipitate of the base hydrochloride salt.
In an embodiment of the present invention, the first organic solvent (used in Step (Aa)) is selected from the group consisting of a cyclic ether, such as pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme, MTBE, and : the like; an aromatic hydrocarbon solvent such as toluene, benzene, xylene, and the like; or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent. Preferably, the first organic solvent (used in step (Aa)) is selected from a cyclic or straight or branched chain dialkyl ether such . as THF, pyran, glyme, MTBE, and the like; more preferably the first organic golvent (used in step (Aa)) : is glyme.
In an embodiment of the present invention, the first organic solvent (used in Step (Aa)) is selected from the group consisting of a cyclic ether, a straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent; wherein the first organic solvent is other than tetrahydrofuran or t-butyl methyl ether.
In an embodiment of the present invention, step (Aa) of the reaction is run such that the compound of formula (IVa) and the base dissolved in the first organic solvent system are reacted with neat sulfuryl chloride; by continuously feeding one reaction stream containing the compound of formula (Iva) and the base dissolved in the first organic solvent system and a second reaction stream containing the sulfuryl chloride into a continuous reactor, preferably a CSTR. In another embodiment of the present invention, the sulfuryl chloride is dissolved in the same organic solvent system as that used to dissolve the compound of formula (IVa) and the base (i.e. the first organic solvent) .
Preferably, the solution containing the compound of formula (Va) and the precipitate of the base hydrochloride salt is filtered, according to known methods, to remove the precipitate.
Preferably, the solution containing the compound of formula (Va) is concentrated by known batch or } continuous methods, for example by evaporation of the solvent (such as by falling film or wiped film : evaporation), or by vacuum distillation, to yield a concentrate of the compound of formula (va). In an embodiment of the present invention, the solution containing the compound of formula (Va) is concentrated to less than or equal to about half the original mass of the solution. In another embodiment of the present invention, the solution containing the compound of formula (Va) is concentrated to an oil.
Wherein the compound of formula (IVa) is reacted with greater than about 1 equivalent of sulfuryl chloride, the solution containing the compound of formula (Va) is preferably concentrated, according to known batch or continuous method, to remove at least about 70% of solvent mass.
Wherein the compound of formula (IVa) is reacted with about 1 equivalent of sulfuryl chloride, the solution containing the compound of formula (Va) is preferably concentrated, according to known batch or continuous method, to remove at least about 20% of solvent mass.
In an embodiment of the present invention, the solution containing the compound of formula (Va) is treated to remove volatiles. Suitable treatments include, but are not limited to vacuum distillation,
concentration, stripping, passing through activated carbon or other absorbent, and the like. ] The concentrate of the compound of formula (Va) is dissolved in a second organic solvent comprising at : least the solvent used in step (Aa), preferably comprising at least one solvent selected from a cyclic ether, such as pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme,
MTBE, and the like; an aromatic hydrocarbon solvent such as toluene, benzene, Xylene, and the like; or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent. Preferably, the concentrate of the compound of formula (Va) is dissolved in the same organic solvent used in step (Aa) above.
Preferably, the concentrate of the compound of formula (Va) is dissolved to a final mass ratio of the solvent to the compound of formula (Va) in the range of from about 2:1 to about 10:1, more preferably to a mass ratio of the solvent to the compound of formula (Va) of about 6:1, to yield a reaction stream for use in step (Ba), hereinafter referred to as the third reaction stream, containing the compound of formula (Va).
In step (Ba), the compound of formula (Va) is reacted with ammonia, preferably ammonia gas; in a second organic solvent comprising at least the solvent used in step (Ra); wherein the second organic solvent comprises at least one solvent selected from a cyclic ether, such as pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme, MTBE, and the like; an aromatic hydrocarbon solvent such as toluene, benzene, xylene, and the like; or a mixture of a cyclic, straight or branched chain dialkyl ether and } an aromatic hydrocarbon solvent; preferably the second organic solvent comprises at least one solvent selected : from a cyclic or straight or branched chain dialkyl ether such as THF, pyran, glyme, MIBE, and the like; more preferably the second organic solvent comprises at least glyme; more preferably still, the second organic solvent is the same as the first organic solvent; more preferably still, the second organic solvent is glyme; wherein the ammonia is preferably present in an amount greater than about 1 molar equivalent of the compound of formula (Va); more preferably, the molar ratio of the ammonia to the compound of formula (Va) is greater than or equal to about 2:1; more preferably still, the molar ratio of the ammonia to the compound of formula (Va) is about 5:1; wherein the temperature of the reaction is preferably maintained in the range of about -30°C to about 50°C, more preferably in the range of about 0°C to about 30°C, more preferably still at about 20°C; to form a solution of the compound of formula (III) and a precipitate.
Preferably, the ammonia gas is fed into the reactor at a controlled pressure or flow rate, more preferably at a pressure in the range of less than or equal to about 30 psia, more preferably still, at a pressure in the range of from about 15 to about 20 psia, more . preferably still, at a pressure of about 19 psia.
In an embodiment of the present invention, the second organic solvent (used in step (Ba)) is selected from the group consisting of a cyclic ether, such as pyran, tetrahydrofuran, and the like; a straight or branched chain dialkyl ether such as glyme, MTBE, and : the like; an aromatic hydrocarbon solvent such as toluene, benzene, xylene, and the like; or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent. Preferably, the second organic solvent (used in step (Ba)) is selected from a cyclic or straight or branched chain dialkyl ether such as THF, pyran, glyme, MTBE, and the like, more preferably the second organic solvent (used in step (Ba)) is glyme.
In an embodiment of the present invention, the second organic solvent (used in Step (Ba)) is selected from the group consisting of a cyclic ether, a straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent; wherein the second organic solvent is other than tetrahydrofuran or t-butyl methyl ether.
Tn another embodiment of the present invention, the second organic solvent (used in step (Ba)) comprises the solvent used in step (Ra) (i.e. the first organic solvent) .
Preferably, the solution containing the compound of formula (III) and the precipitate is filtered by known methods, to remove the precipitate.
In an embodiment of the invention, the process for the preparation of a compound of formula (III) is run in two continuous stirred tank reactors (CSTRs).
Preferably, step (Aa) is run such that the residence time in the first CSTR is about 1 hour. Preferably, . step (Ba) is run such that the residence time in the second CSTR is about 3 hours. Preferably, step (Ba) is : run such that the third reaction stream and ammonia are introduced above surface into the CSTR.
One skilled in the art will recognize that any of the processes of the present invention may be used to prepare racemic mixtures of a compound of the formula (I) or any of the stereoisomers of a compound of formula (I), by selection and substitution of appropriate racemic mixtures or stereoisomers of the reagents.
Where the compounds according to this invention have at least one chiral center, they may accordingly exist as enantiomers. Where the compounds possess two or more chiral centers, they may additionally exist as diastereomers. It is to be understood that all such isomers and mixtures thereof are encompassed within the scope of the present invention. Furthermore, some of the crystalline forms for the compounds may exist as polymorphs and as such are intended to be included in the present invention. In addition, some of the compounds may form solvates with water (i.e., hydrates) or common organic solvents, and such solvates are also intended to be encompassed within the scope of this invention. © 30
Where the processes for the preparation of the compounds according to the invention give rise to a mixture of stereoisomers, these isomers may be separated by conventional techniques such as preparative chromatography. The compounds may be prepared in racemic form, or individual enantiomers may be prepared ) either by enantiospecific synthesis or by resolution.
The compounds may, for example, be resolved into their ’ component enantiomers by standard techniques, such as the formation of diastereomeric pairs by salt formation with an optically active acid, such as (-) -di-p-toluoyl-
D-tartaric acid and/or (+)-di-p-toluoyl-L-tartaric acid followed by fractional crystallization and regeneration of the free base. The compounds may also be resolved by formation of diastereomeric esters or amides, followed by chromatographic separation and removal of the chiral auxiliary. Alternatively, the compounds may be resolved using a chiral HPLC column.
During any of the processes for preparation of the compounds of the present invention, it may be necessary and/or desirable to protect sensitive or reactive groups on any of the molecules concerned. This may be achieved by means of conventional protecting groups, such as those described in Protective Groups in Organic
Chemistry, ed. J.F.W. McOmie, Plenum Press, 1973; and
T.W. Greene & P.G.M. Wuts, Protective Groups in Organic
Synthesis, John Wiley & Sons, 1991. The protecting groups may be removed at a convenient subsequent stage using methods known from the art.
The following examples describe the invention in greater detail and are intended to illustrate the invention, but not to limit it.
Example 1
Preparation of Diacetone-f-D- fructose chlorosulfate (CS)
Continuous Process . A DAF stock solution was prepared by weighing out diacetone-B-fructose (DAF) (911.0 g) into a one gallon ) glass bottle. To the solids were added glyme (2113.5 g, 2450 mL) and pyridine (290.7 g, 297 mL) and the solution was stirred to complete dissolution of the DAF.
Additional stock solution was made as necessary.
A 1-liter Erlemeyer flask was filled with DAF stock solution (936.8 g, 987.2 mL) and placed on a top loading balance. A piston pump was configured to pump the solution into the reactor.
Into a separate flat-bottom boiling flask was weighed sulfuryl chloride (SC) (172.2 g, 103.8 mL) and the flask was immediately stoppered. The SC containing flask was then placed on a top loading balance and a . second piston pump was set up to pump the SC into the reactor.
The reactor was a continuous stirred glass reactor with a four-necked head and a side overflow port at approximately the l-liter level. A nitrogen pad utilizing a back-pressure bubbler was applied to the reactor. The material in the reactor from the previous experiment was determined to contain 0.3% DAF, 99.7% CS and 0.08% other unidentified material.
The piston pump for the SC was started at a feed rate of 2.2 g per min. When the SC reached the reactor, the piston pump for the DAF stock solution was started . at a feed rate of 15.2 g per min.
The reactor cooling system was set at -15°C in an attempt to maintain the reaction temperature near 0°C during the course of the reaction; a temperature in the range of +4.0°C to +5.0°C was achieved. The reactor was stirred at 400 rpm. : The reactor was run continuously for a period of seven (7) hours, with the SC and DAF stock solution feed ) reservoirs replenished as required. Balance readings were used to monitor addition rates and the pump settings adjusted to maintain feed rates. The residence time within the reactor was calculated at about one (1) hour.
The receiving flask was replaced hourly, with the : product stream filtered and then evaporated to an oil on a rotary evaporator with a water bath maintained at a temperature of about 40°C. Each aliquot of concentrated oil was transferred to a glass bottle and placed in a freezer at -20°C for storage.
The product stream from the reactor was also sampled hourly and analyzed via GC with results as listed in Table 1, below:
Table 1: Product Stream Contents
I LL BLL
A 2000 ow ee | ow ’ Example 2
Preparation of Topiramate (TPM) Continuous Process cS feed solution was prepared by reconstituting the oil prepared as in Example 1, by dissolving in glyme to a final concentration of 1 gm CS to 5.8 gms glyme as . follows. The CS oil (376.1 g) was removed from the freezer (where it was stored between runs to avoid ‘ decomposition) and allowed to warm to room temperature.
The CS was rinsed into a 4-liter Erlemeyer flask with portions of glyme. Glyme was added to the desired ratio, for a total glyme addition of 2181.33 gms. The solution was mixed well and filtered through a 934-AH glass-fiber filter pad using mild vacuum, to yield a CS stock solution (2523.2 g).
A 2-liter stainless steel reactor with overflow port at about the 1.5 liter level was isolated from a 20 liter stainless steel product receiver. The product receiver was evacuated to a vacuum of 30” Hg using a water aspirator.
The reactor cooling system was set to 16.5°C and was thereafter adjusted in stages to a final setting of 13°C to maintain the interior reaction temperature between 17.9°C and 19.9°C during the course of the reaction. The reactor was stirred at 700 rpm.
The entire reactor system was pressurized to about 2 psig (17 psia) with anhydrous ammonia. During the reaction run, the ammonia was continuously added under pressure control, maintaining a system pressure level of between 2 psig (17 psia) and 3 psig (18 psia). The } measured ammonia pressure was in the range of 1.5 psig (16.2 psia) to 2.5 psig (17.2 psia).
The CS feed solution was weighed before and after use. The reservoir containing the CS feed solution was placed on a top loading balance and a stream of nitrogen was maintained at the surface of the liquid. The CS feed solution was continuously added to the reactor via a piston pump at a rate of about 7.1 g per min. As more
CS feed solution was needed, it was prepared as previously described and the reservoir replenished.
The reactor was run continuously for sixteen (16) hours, with overflow collected in the product receiver can. The overflow was monitored by HPLC for composition, including amount of product (Topiramate), amount of DAF, amount of CS, and amount of “other” byproducts, with results as listed in Table 2, below.
Table 2: Product Stream Contents
IE IE NEA MEIC I
IE NC NE BE NCE
I IC I NEE
I EEC NE NE BL
I I CECI NEE I
Ml CL NZL NE LE
Ml A EA NEEL CE
Ii ET CE LC BC
IE CZ NI BEN NC
After 16 hours, the reactor was turned off and the product receiver can was allowed to sit under ammonia pressure of about 2.0 psig (17 psia) for about 8 hours.
The product receiver can was then vented to allow most of the ammonia to escape.
The product slurry was filtered in a Buchner funnel. The solids were slurried in the Buchner funnel . and drained thoroughly with two nearly equal portions of fresh glyme (total weight 172.2 g). The filtered contents of the product receiver can and washings weighed 6321.8 g, while the wetcake of washed solids weighed 194.6 gms.
The filtered solution was evaporated to an oil on a rotary evaporator with a water bath maintained at a temperature of 40°C to yield crude Topiramate.
GC analysis of the solution in the product receiver after sixteen (16) hours reaction time showed a mixture of 1.1 Area % DAF, 8.0 Area % CS, 90.6 Area % TPM and 0.3 Area % unknowns.
GC analysis of the solution in the product receiver after sixteen (16) hours reaction time and about 8 hours standing showed a mixture of 0.9 Area % DAF, no CS, 98.5
Area % TPM and 0.6 Area % unknowns.
GC analysis of the contents of the product receiver after filtration showed a mixture of 1.7 Area % DAF, no
CS, 97.9 Area % TPM and 0.5 Area % unknowns.
Example 3
Preparation of Diacetone-B-D-fructose chlorosulfate (CS)
Continuous Process
The reactor used was a continuously stirred glass reactor with a four-necked head, a side overflow port at approximately the 1-liter level, and a nitrogen pad utilizing a back-pressure bubbler. The reactor was cooled with an indirect glycol cooling system. Prior to the start of the experiment, the material in the reactor was analyzed by GC. The starting reactor compositions for completed runs were as summarized in Table 3. . : Table 3: Starting Reactor Composition
Ec WC Hl NN A
IR 2 al nl al
CL 2 IZ IEC IEE ICE IH
CE CH NC NC NC IES NL
A 1-liter Erlenmeyer flask was filled with DAF stock solution (prepared as described in Example 1) and was placed on a top loading balance. A piston pump was configured to pump the solution into the reactor. sul furyl chloride (SC) was weighed into a separate flat- bottom boiling flask. The flask containing the sulfuryl chloride was stoppered and then placed on a top loading balance. A second piston pump was configured to pump the SC into the reactor.
Agitation was started at about 400 rpm, and the piston pump for the SC was started at the desired feed rate. When the SC reached the reactor, the piston pump for the DAF stock solution was started at the desired rate. The reactor was run continuously for a set period of hours, with the SC and DAF stock solutions feed reservoirs replenished as required. The reactor product overflowed continuously to a product receiver that was emptied as needed. Balance readings were used to monitor addition rates and the pump settings adjusted to maintain feed rates. Operating conditions, including the calculated reactor residence times, were as summarized in Table 4, below.
Table 4: Reactor Operating Conditions
FH NC HC
} Mole Ratio
EO
. Mole Ratio
Mole Ratio
Pump rate (g/min)
Pump rate (g/min) a Hc NC HC HC IE
Residence Time
The reactor was sampled hourly and the samples analyzed for content by GC. The hours of operation at each condition and the resulting reactor content near completion of the continuous operation are summarized in
Table 5, below.
Table 5: Operating Time & Reactor Contents
RL NC NN CA BC I
SO IC CA CA CN HC BC
. Example 4
Preparation of Topiramate (TPM) Continuous Process
The continuous reactor was a 2-liter stainless steel pressure reactor with an overflow port at about the 1.5 liter level. The product receiver was a 20- ] liter stainless steel pressure tank. The reactor was cooled with an indirect glycol cooling system to . maintain the temperature near the targeted temperature during the course of the reaction. Prior to the start of the experiment, the material in the reactor from the previous experiment was analyzed by GC to determine content. The starting reactor compositions were summarized in Table 6, below.
Table 6: Reactor Contents at Start of Experiment
DE Nc Wl Hl ll Hl Hl Bll a ed 2 a a Ee
I FC CE HCE HC NC
CIE NECN IEC FL Nl cl I
IC a a a i a (od
A CE NC HC A HCA HC
Ak EC cd EC ll dd
At the start of the experiment, the product receiver was evacuated and the entire reactor system was pressurized to the target pressure with anhydrous ammonia gas. With the exception of Run #10, the ammonia was added above surface. A reservoir containing CS solution, prepared as described in Example 2, was placed on a top loading balance and blanketed (inerted) with nitrogen. A piston pump was configured to pump the CS solution continuously into the reactor. With the exception of Run #10 and #11, the CS solution was added to the reactor above surface.
The piston pump for the CS solution was started at the target feed rate. Ammonia was continuously added under pressure control to maintain the target pressure.
The reactor product overflowed continuously to the product receiver. As more CS feed solution was needed, . it was prepared as described in Example 2. Operating conditions, including the calculated reactor residence time, were summarized in Table 7, below.
Table 7: Reactor Operating Conditions
Ea a cl Nl Fi Nc
Mass Ratio % DAF in CS
CS solution Feed
NH; pressure at mmr Leanne en
Agitator speed
EC Nc FE EN JE CN
Residence time
Mass Ratio
Ele PP FY % DAF in CS fem leafs fee [ee]
CS solution Feed
BN vl PY PL PU
EL IR NC a NE NEL
Claims (51)
1. A continuous process for the preparation of a compound of formula (I) o HM _ X 5 NR . ne Yo R3 R® RR (1) wherein X is selected from CH, or O; R! is selected from the group consisting of hydrogen and C;-galkyl; R3, R*, R® and R® are each independently selected from hydrogen or lower alkyl and, when X is CH, R® and R® may be alkene groups joined to form a benzene ring and, when X is 0, R® and R! and/or R® and R® together may be a methylenedioxy group of the formula: Rr’ 0-9 XK R® 0-% wherein R? and R® are same or different and are hydrogen, lower alkyl or are alkyl and are joined to form a cyclopentyl or cyclohexyl ring; comprising S02Cl X OH X O (oe + SO,Cly ——» (pw R R* R® R* (IV) V)
(A) reacting a suitably substituted compound of formula (IV) with sulfuryl chloride; in the presence of an organic or inorganic base; . in a first organic solvent comprising at least one solvent selected from a cyclic ether, a straight or : branched chain dialkyl ether, an aromatic hydrocarbon, or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent; to form the corresponding compound of formula (V); 50,C S0,~NHR' X 0] X oO Se + R'—NH, ——— Se R® R* Vi RS rR? Vv) (1 (B) reacting the compound of formula (V) with a suitably substituted compound of formula (VI); in a second organic solvent comprising at least the solvent used in step (A); to form the corresponding compound of formula (I).
2. The process as in Claim 1, wherein the organic or inorganic base is an organic base.
3. The process as in Claim 2, wherein the organic base is pyridine.
4, The process as in Claim 1, wherein the first organic solvent comprises at least one solvent selected the group consisting of a cyclic ether, a straight or branched chain dialkyl ether, an aromatic hydrocarbon solvent and a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent.
i
5. The process as in Claim 4, wherein the first organic solvent comprises a cyclic ether or a straight . or branched chain dialkyl ether.
6. The process as in Claim 5, wherein the first organic solvent is glyme.
7. The process as in Claim 1, wherein the sulfuryl chloride is present in an amount greater than about 0.9 moles per mole of the compound of formula (IV).
8. The process as in Claim 1, wherein the base is present in an amount greater than about 1 molar equivalent of the compound of formula (IV).
9. The process as in Claim 8, wherein the molar ratio of the compound of formula (IV) to the base is at least about 1:1.05.
10. The process as in Claim 1, wherein the temperature of the reaction in Step (A) is less than about 50°C.
11. The process as in Claim 1, wherein the second organic solvent is glyme.
12. The process as in Claim 1, wherein the compound of formula (VI) is present in an amount greater than about 1 molar equivalent of the compound of formula (V).
13. The process as in Claim 12, wherein the molar ratio of the compound of formula (VI) to the compound of formula (V) is at least about 2:1.
14. The process as in Claim 1, wherein the compound of ’ formula (VI) is ammonia and the ammonia is fed into the reactor at a pressure of about 19 psia.
15. The process as in Claim 1, wherein the temperature of the reaction in Step (B) is in the range of from about -30 to about 50°C.
16. The process as in Claim 1, wherein the compound of formula (V) is formed in a solution comprising the compound of formula (V) and the first organic solvent.
17. The process as in Claim 16, wherein the sulfuryl chloride is reacted in amount equal to about 1 equivalent relative to the compound of formula (IV), further comprising concentrating the solution comprising the compound of formula (V) and the first organic solvent to remove at least about 20% of the solvent mass. .
18. The process as in Claim 16, wherein the sulfuryl chloride is reacted in amount greater than about 1 equivalent relative to the compound of formula (IV), further comprising concentrating the solution comprising the compound of formula (V) and the first organic solvent to remove at least 70% of the solvent mass.
19. The process as in Claim 16, further comprising concentrating the solution comprising the compound of formula (V) and the first organic solvent to an oil.
20. The process as in Claim 16, further comprising
. treating the solution comprising the compound of formula (V) and the first organic solvent to remove volatiles.
21. The process as in Claim 1, wherein step (A) and step (B) are each run in a continuous stirred tank reactor.
22. A compound prepared according to the process of Claim 1.
23. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of Claim 22.
24. A pharmaceutical composition made by mixing a pharmaceutically acceptable carrier and the compound of Claim 22.
25. A process for making a pharmaceutical composition comprising mixing a pharmaceutically acceptable carrier and the compound of Claim 22.
26. A continuous process for the preparation of a compound of formula (III)
SO,—NH, oO / 0 SI TT (11) comprising SOC O §& OH Q& 0 om ~0 + SO,Cl, ——= OW ~po NI 3 (IVa) (Va) (Aa) reacting a compound of formula (IVa) with sulfuryl chloride; in the presence of an organic or inorganic base; in a first organic solvent comprising at least one solvent selected from a cyclic ether, a straight or branched chain dialkyl ether, an aromatic hydrocarbon, or a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent; to form the corresponding compound of formula (Va); Cl — o S02 S02 NH, ow ~~Q + NH; ——— {0 oA oe (Va) (Hn) } (Ba) reacting the compound of formula (Va) with ammonia; : in a second organic solvent comprising at least the solvent used in step (A);
to form the corresponding compound of formula }
27. The process as in Claim 26, wherein the organic or inorganic base is an organic base.
28. The process as in Claim 27, wherein the organic base is pyridine.
29. The process as in Claim 26, wherein the first organic solvent comprises at least one solvent selected from the group consisting of a cyclic ether, a straight or branched chain dialkyl ether, an aromatic hydrocarbon solvent and a mixture of a cyclic, straight or branched chain dialkyl ether and an aromatic hydrocarbon solvent.
30. The process as in Claim 29, wherein the first organic solvent comprises a cyclic ether or a straight or branched chain dialkyl ether.
31. The process as in Claim 30, wherein the first organic solvent is glyme.
32. The process as in Claim 26 wherein the sulfuryl chloride is present in an amount greater than about 0.9 moles per mole of the compound of formula (IVa).
33. The process as in Claim 26, wherein the base is present in an amount greater than about 1 molar equivalent of the compound of formula (IVa).
34. The process as in Claim 33, wherein the molar ratio of the compound of formula (IVa) to the base is at least about 1:1.05.
35. The process as in Claim 26, wherein the temperature ‘ of the reaction in Step (Aa) is less than about 50°C.
36. The process as in Claim 26, wherein the second organic solvent is glyme.
37. The process as in Claim 26, wherein the ammonia is present in an amount greater than about 1 molar equivalent of the compound of formula (Va).
38. The process as in Claim 37, wherein the molar ratio of the ammonia to the compound of formula (Va) is at least about 2:1.
39. The process as in Claim 26, wherein ammonia is fed into the reactor at a pressure of about 19 psia.
40. The process as in Claim 26, wherein the temperature of the reaction in Step (Ba) is in the range of from about -30 to about 50°C.
41. The process as in Claim 26, wherein the compound of formula (Va) is formed in a solution comprising the compound of formula (Va) and the first organic solvent.
42. The process as in Claim 41, wherein the sulfuryl chloride is reacted in amount equal to about 1 equivalent relative to the compound of formula (IVa), further comprising concentrating the solution comprising the compound of formula (Va) and the first organic solvent to remove at least about 20% of the solvent mass.
43. The process as in Claim 41, wherein the sulfuryl ’ chloride is reacted in amount greater than about 1 equivalent relative to the compound of formula (IVa), further comprising concentrating the solution comprising the compound of formula (Va) and the first organic solvent to remove at least 70% of the solvent mass.
44. The process as in Claim 41, further comprising concentrating the solution comprising the compound of formula (Va) and the first organic solvent to an oil.
45. The process as in Claim 41, further comprising treating the solution comprising the compound of formula (Va) and the first organic solvent to remove volatiles.
46. The process as in Claim 26, wherein step (Bb) is run in a continuous stirred tank reactor.
47. The process as in Claim 26, wherein step (Aa) and step (Ba) are each run in a continuous stirred tank reactor.
48. A compound prepared according to the process of Claim 26.
49. A pharmaceutical composition comprising a pharmaceutically acceptable carrier and the compound of Claim 48.
50. A pharmaceutical composition made by mixing a pharmaceutically acceptable carrier and the compound of Claim 48.
51. A process for making a pharmaceutical composition ’ comprising mixing a pharmaceutically acceptable carrier and the compound of Claim 48.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42255802P | 2002-10-31 | 2002-10-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ZA200504408B true ZA200504408B (en) | 2006-08-30 |
Family
ID=35964229
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ZA200504408A ZA200504408B (en) | 2002-10-31 | 2005-05-30 | Continuous process for the preparation of fructopyranose sulfamate derivatives |
Country Status (4)
| Country | Link |
|---|---|
| CN (1) | CN100430408C (en) |
| CL (1) | CL2003002220A1 (en) |
| UA (1) | UA80450C2 (en) |
| ZA (1) | ZA200504408B (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2011096934A1 (en) * | 2010-02-05 | 2011-08-11 | Scinopharm Taiwan, Ltd. | Process for the preparation and purification of topiramate |
| CN106397502A (en) * | 2016-08-31 | 2017-02-15 | 安徽省润生医药股份有限公司 | Synthesis technology of topiramate |
| CN114350340B (en) * | 2022-01-13 | 2023-01-17 | 陕西科技大学 | Permeation enhancer for fracturing and preparation method and application thereof |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU651244B2 (en) * | 1991-09-19 | 1994-07-14 | Mcneilab, Inc. | Process for the preparation of chlorosulfate and sulfamate derivatives of 2,3:4,5-bis-0-(1-methylethylidene)-beta-D- fructopyranose and (1-methylcyclohexyl)methanol |
-
2003
- 2003-10-27 UA UAA200504673A patent/UA80450C2/en unknown
- 2003-10-27 CN CNB2003801077369A patent/CN100430408C/en not_active Expired - Fee Related
- 2003-10-30 CL CL2003002220A patent/CL2003002220A1/en unknown
-
2005
- 2005-05-30 ZA ZA200504408A patent/ZA200504408B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| UA80450C2 (en) | 2007-09-25 |
| CL2003002220A1 (en) | 2005-01-14 |
| CN1732179A (en) | 2006-02-08 |
| CN100430408C (en) | 2008-11-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA200507995B (en) | Process for the preparation of anticonvulsant derivatives of topiramate | |
| US20060105966A1 (en) | Novel anticonvulsant derivative salts | |
| Van Boom et al. | The application of levulinic acid as protective group to the synthesis of tetradecaribonucleotide U‐A‐U‐A‐U‐A‐U‐A‐U‐A‐U‐A‐U‐A via the modified phosphotriester method | |
| IE893360L (en) | Tumour-inhibiting saccharide conjugates | |
| CA3088410A1 (en) | Stereoselective synthesis and process for the manufacturing of 2'-deoxynucleosides | |
| AU2002346042A1 (en) | Novel anticonvulsant derivative salts | |
| ZA200504408B (en) | Continuous process for the preparation of fructopyranose sulfamate derivatives | |
| Panday et al. | Synthesis and Evaluation of Indolizine‐Type Inhibitors of N‐acetyl‐β‐d‐glucosaminidases | |
| EP1558624B1 (en) | Continuous process for the preparation of fructopyranose sulfamate derivatives | |
| US4021542A (en) | Derivatives of hydrazino-monosaccharides and aldohexoses which are useful as intermediates for preparing compounds or as compounds which lower the uric acid | |
| Binkley et al. | Synthesis of dideoxy sugars by triflate rearrangement | |
| Dent et al. | Synthesis studies of structural analogues of tagetitoxin: 4-O-acetyl-3-amino-1, 6-anhydro-3-deoxy-d-gulose 2-phosphate | |
| US4656260A (en) | Cyclic pyrazolo C-nucleoside compound and process for preparing the same | |
| AU2003300149A1 (en) | Novel anticonvulsant derivative salts | |
| ZA200510347B (en) | Asphalt-epoxy resin compositions | |
| Costa et al. | Acyclic nucleoside analogues from thymine-substituted thymidines and related compounds | |
| CN103254120B (en) | Spiro-azasugar quaternary ammonium salt compound, and preparation method and application thereof | |
| McDonough | The synthesis of some N-linked carba-sugars as glycosidase inhibitors | |
| Schubert et al. | Aminoglycoside Antibiotics–Fortamine Aglyca Total Synthesis, Optical Resolution, Chemical Modifications |